Teva Pharmaceutical Industries Ltd was incorporated in Israel on February 13, 1944. The Company manufactures generic pharmaceutical products. It operates in business in two segments generic and specialty medicines. The generics segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients ("API"). The specialty segment engages in the development, manufacture, sale and distribution of branded specialty medicines such as those for central nervous system and respiratory indications, as well as those marketed in the women's health, oncology and other specialty businesses. Its other activities include the over-the-counter ("OTC") medicines business, distribution activity mainly in Israel and Hungary and medical devices. The OTC activity is mainly conducted through a joint venture with P&G, which combines Company's production capabilities and market reach with P&G's marketing expertise and expansive platform. It has market presence in the United States, Europe and other markets. The Generic medicines include chemical and therapeutic equivalents of originator medicines in dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. The Specialty medicines include several franchises in the core therapeutic areas of CNS medicines such as Copaxone, Azilect, Nuvigil and Zecuity and of respiratory medicines such as ProAir HFA and QVAR. It also includes other therapeutic areas, such as oncology medicines, including Treanda, women's health and selected other areas. The Company is subject to extensive regulation by the United States federal government, principally by the FDA and the Drug Enforcement Administration ("DEA").